Stoke Therapeutics (NASDAQ:STOK) Now Covered by Jefferies Financial Group

Investment analysts at Jefferies Financial Group initiated coverage on shares of Stoke Therapeutics (NASDAQ:STOK - Get Free Report) in a report released on Friday, MarketBeat.com reports. The firm set a "buy" rating and a $30.00 price target on the stock. Jefferies Financial Group's price target points to a potential upside of 126.93% from the stock's previous close.

STOK has been the topic of several other research reports. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Tuesday, July 1st. HC Wainwright dropped their price target on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Finally, Cantor Fitzgerald raised Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, Stoke Therapeutics presently has an average rating of "Buy" and a consensus price target of $25.80.

Stoke Therapeutics Stock Performance

Shares of Stoke Therapeutics stock traded up $0.87 during trading on Friday, hitting $13.22. 1,552,675 shares of the stock traded hands, compared to its average volume of 678,585. The stock has a market cap of $721.77 million, a P/E ratio of 16.73 and a beta of 1.14. Stoke Therapeutics has a twelve month low of $5.35 and a twelve month high of $16.15. The company has a fifty day moving average price of $10.97 and a two-hundred day moving average price of $9.63.

Insiders Place Their Bets

In other Stoke Therapeutics news, insider Barry Ticho sold 6,471 shares of Stoke Therapeutics stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $10.03, for a total value of $64,904.13. Following the completion of the transaction, the insider directly owned 25,782 shares of the company's stock, valued at $258,593.46. The trade was a 20.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 9.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors have recently made changes to their positions in STOK. GAMMA Investing LLC lifted its holdings in shares of Stoke Therapeutics by 1,842.0% in the first quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock valued at $36,000 after purchasing an additional 5,084 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Stoke Therapeutics during the fourth quarter valued at approximately $63,000. AlphaQuest LLC purchased a new stake in Stoke Therapeutics in the first quarter worth $72,000. US Bancorp DE increased its position in Stoke Therapeutics by 9,743.9% in the first quarter. US Bancorp DE now owns 11,222 shares of the company's stock worth $75,000 after buying an additional 11,108 shares during the last quarter. Finally, Fox Run Management L.L.C. purchased a new stake in Stoke Therapeutics in the first quarter worth $92,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.